上海谊众：2025年全年净利润同比预增760.18%—903.54%

Core Viewpoint - Shanghai Yizhong has announced an annual performance forecast, expecting a significant increase in net profit for 2025 due to the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 60 million to 70 million yuan for 2025, representing a year-on-year increase of 760.18% to 903.54% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 56 million and 66 million yuan, indicating a year-on-year growth of 1338.87% to 1595.81% [1] Product Impact - The significant growth in revenue and profit compared to 2024 is primarily driven by the market access and increased patient numbers for the company's core product, paclitaxel micelles, following its formal inclusion in the national medical insurance catalog in 2025 [1]